NCT05147155View on ClinicalTrials.gov

Impulse Oscillometry Measurements in Severe Eosinophilic Asthmatics Before and After Anti-IL-5 Factor Initiation

CompletedOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

October 23, 2023

Study Completion Date

October 23, 2023

Conditions
Severe Asthma
Interventions
BIOLOGICAL

Mepolizumab

This will be a 2-year prospective study. Patients with uncontrolled severe asthma will receive mepolizumab according to standard of care and best clinical practice, which will be administered as a 100-mg subcutaneous dose every four weeks.

Trial Locations (1)

41110

External Unit of Asthma of Respiratory Medicine Department of the University of Thessaly in Greece, Larissa

All Listed Sponsors
lead

University of Thessaly

OTHER